IL-APTARGROUP
26.5.2021 14:32:09 CEST | Business Wire | Press release
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, announces the launch of the company’s first fully recyclable mono-material pump for the beauty and personal care industries, called Future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210526005198/en/
Certified and Sustainable by Design
In order to facilitate recycling, Future was designed using polyethylene (PE) mono-material only. Future is certified by Cyclos-HTP, the institute for Recyclability and Product Responsibility * . The innovation is also recognized “A” by RecyClass – a comprehensive cross-industry initiative that works to establish a harmonized recycling approach and traceability in Europe*.
“Today we are pleased to launch our latest sustainable innovation, Future, a game changing dispensing solution. Following more than two years of design, engineering and testing, I am very proud of our team’s mono-material design and it truly reflects our commitment to a more circular economy,” said Marc Prieur, President, Aptar Beauty + Home.
In developing the concept for Future, Aptar’s experts turned to recognized eco-design principles, which call for plastic dispensing products to be made from a mono-material to facilitate the recycling process. Traditional pumps may contain different materials, including metal components that can in some cases complicate the recycling process. Because the Future pump is made from PE only, it also aligns with the most common materials used to make bottles – PE and PET. Therefore, the complete packaging, including pump and bottle, are more easily recycled*.
Christophe Marie, Product Sustainability Director, Aptar, explains, “The ideal situation for the complete value chain is to have mono-material packaging where the container, the closure or dispensing system is made from the same material family. This was the big challenge our innovation team overcame with the development of Future.”
*Subject to local recyclability facilities and fully recyclable with PET and PE bottles.
RecyClass recognition applies for an undecorated clear or white pump.
Future is also available using post-consumer resin (PCR). Aptar Beauty + Home proudly obtained an International Sustainability & Carbon Certification (ISCC) for its European production.
“Our ultimate goal was to have the final consumer be able to take their body lotion, shampoo or shower gel and easily put the empty packaging in their recycling bin. This way, it enters a circular life cycle and can be turned into another product,” explained Sabine Bouillet-Lubot, Global Strategic Marketing Director, Aptar Beauty + Home.
E-Commerce Capable & Eco-Design
The Future pump combines the best eco-design principles with cutting-edge innovation. A stand-out feature of the Future pump’s innovative design is an incorporated on/off locking system and a 360° degree actuator. This modern take on closure design also renders Future compliant with the rigorous ISTA 6-Amazon protocol**. Designed for e-commerce, Future’s ISTA 6 compliance ensures that the pump withstands the risks associated with transport and distribution network pressures as well as necessitates less protective carton and paper packaging.
**Subject to final tests conducted by a brand’s bottle choice.
Sustainability at Aptar
Aptar believes that the packaging industry must move beyond the make, use, dispose behaviors of the past and actively work toward a circular economy. By circulating used plastic and packaging, we keep it in the economy and out of the environment. Therefore, reducing the quantity of plastic needed, using recycled materials and developing reuse models. Our vision is to design products and processes with people and the planet in mind and we are focusing our activities on three mains areas for sustainability: recycled materials, recyclability and reusability. Collaboration is essential to achieving a more circular economy, so we work with partners, suppliers and customers who share our vision. As a member of the Ellen MacArthur Foundation’s New Plastics Economy Global Commitment, this innovation highlights our pledge to reduce environmental impact and support the Foundation’s vision for a circular economy. We are working hard towards our 2025 goal to have all of our packaging 100% reusable, recyclable or compostable for our dispensing solutions for the beauty, personal care, home care and food and beverage markets.
Aptar to Present at the ChangeNow 2021 Global Summit
Aptar’s innovative dispensing solution will be introduced live at the ChangeNOW 2021 Global Summit on May 27th. As a proud supporting partner of ChangeNOW, Aptar’s Vice President of Global Sustainability, Beth Holland, will be a featured guest speaker during the circular economy panel discussion.
About Aptar
Aptar is a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com .
This press release contains forward-looking statements. Expressions or future or conditional verbs such as “will” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the successful integration of acquisitions; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-Ks and Form 10-Qs. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005198/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release
A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel
China's ~$900B Live-Commerce Market Now Approaches US E-Commerce Scale17.7.2026 12:30:00 CEST | Press release
The consumer habits reshaping global retail were built in the East — and most Western shoppers haven't yet adopted them. NIQ report shows that brands still treating live, social, and quick commerce as "emerging" risk being left behind. The center of gravity in global retail has shifted East. The formats now driving the fastest growth in global retail (live shopping, social commerce, and delivery in minutes) were pioneered and scaled in Asia, and most Western consumers have yet to adopt them. According to NIQ (NYSE: NIQ), a leading consumer intelligence company, in its global report The Commerce Revolution: Where East Meets West, the gap between East and West is still vast. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717253489/en/ China´s USD 900bn live shopping boom now approaches the scale of the US E-commerce The scale is already substantial. China's live-commerce market alone was worth roughly $900 billion in 2025,
Ant International’s Alipay+ Connects Argentina's National QR Payment Scheme via PVS,Enabling for Cross-Border Digital Payment Nationwide at Millions of Merchants17.7.2026 12:17:00 CEST | Press release
Alipay+, a global digital payment gateway under Ant International, today announced that it will enable global travellers to make QR code payments at millions of merchants across Argentina through integration with the country's national QR payment scheme Transferencias 3.0, in partnership with PVS, a fintech company specialized in developing customized payment solutions in Latin America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717276406/en/ By connecting to Argentina's national QR payment scheme, Alipay+ now enables global travellers in the country to make convenient QR code payments at merchants nationwide. This service helps to enhance global travellers' travel experiences in Argentina, allowing them to pay seamlessly at restaurants, malls and tourist attractions. Using an Alipay+ partner payment app, they can now scan the national QR code displayed at all merchants to make cross-border payments across Argentina,
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
